An interventional study of Health Belief Model-Based Education Program in Breast Self-Examination and Breast Cancer, sponsored by Kafkas University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 20 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-16.
Sponsored by Kafkas University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 400 studies in Breast Neoplasms with a site in Turkey — 83 open to participants now, 129 under way, 46 of them phase 3. Breast Neoplasms · Turkey.
Among the 400 studies in Breast Neoplasms with a site in Turkey, this one is the 196th largest by planned enrollment of the 321 interventional ones that give a count, is one of 40 that started in 2026, is one of 184 with no phase, reaches primary completion later than 56 of the 128 other live ones, and was the 350th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →83 of the 400 studies in Breast Neoplasms with a site in Turkey are open now. Recruiting first, the newest first:
Pamukkale University · Sites in Turkey
Ages 18+ · Women only · Healthy volunteers
Bursa City Hospital · Sites in Turkey
Ages 18–85 · Women only
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey · Sites in Turkey
Ages 18–65 · Women only
Ege University · Sites in Turkey
Ages 18+ · Women only
Mucahide Emine Fidancı Kuas · Sites in Turkey
Ages 18–85 · Women only · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 20 Years to 69 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
400 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 36 · Phase 3 98 · Phase 4 5
First in 1996; this study’s year is marked. 40 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 76 is close to the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 100 across the 321 interventional studies, 80 across the 79 observational. Of the 247 that completed or were terminated, 67 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
131 of 400 have an industry lead sponsor. The 10 most frequent:
Kafkas University is the lead sponsor of 32 studies on the registry; 11 are open to participants now.
Kafkas University has 2 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
34 of the studies in Breast Neoplasms with a site in Turkey that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04873362Phase 3Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | 2027-03-31 |
| NCT05696626Phase 3LeonaBioEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | 2027-04 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT05774951Phase 3AstraZenecaA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | 2027-04-20 |
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
Add all 34 to your calendar (.ics) → With an account.
Among the 400 studies in Breast Neoplasms with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study titled "The Effect of a Health Belief Model-Based Training Program on Women's Self-Breast Examination Behavior, Breast Cancer Fear and Awareness Levels: A Randomized Controlled Study" aimed to increase breast cancer awareness and the application of breast self-examination techniques among women by providing the necessary training through a training program based on the Health Belief Model.
This randomized controlled study aims to evaluate the effectiveness of a Health Belief Model-based education program on women's breast self-examination practices, breast cancer fear, and awareness levels. Participants will be randomly assigned to either an intervention group receiving a structured education program based on the Health Belief Model or a control group receiving usual care.
Data will be collected using a Personal Information Form, the Champion Health Belief Model Scale, the Comprehensive Breast Cancer Knowledge Test, the Breast Cancer Awareness Scale, and the Champion Breast Cancer Fear Scale at baseline and three months after the intervention. The findings of this study are expected to contribute to the development of effective educational strategies for improving breast cancer awareness and preventive health behaviors among women.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
This study's planned enrollment of 76 is close to the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Kafkas University is the lead sponsor of 32 studies on the registry; 11 are open to participants now.
Compared within Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Self-Examination. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants receive a structured education program based on the Health Belief Model focusing on breast self-examination.
Behavioral: Health Belief Model-Based Education Program
Participants receive usual care without any additional educational intervention.
A structured education program based on the Health Belief Model designed to improve breast self-examination behavior and increase breast cancer awareness.
Change in Breast Self-Examination Behavior
Change in breast self-examination behavior measured as a single self-reported outcome indicating whether participants perform breast self-examination.
Time frame: Baseline and 3 months after the intervention
Change in Breast Cancer Knowledge Level
Change in breast cancer knowledge assessed using the Comprehensive Breast Cancer Knowledge Test.
Time frame: Baseline and 3 months after the intervention
Change in Breast Cancer Awareness Level
Change in breast cancer awareness measured using the Breast Cancer Awareness Scale.
Time frame: Baseline and 3 months after the intervention
Change in Breast Cancer Fear Level
Change in fear related to breast cancer measured using the Champion Breast Cancer Fear Scale.
Time frame: Baseline and 3 months after the intervention
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2026; primary completion for Jun 2026, 5 months later.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 5 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kafkas University